API Holdings, the parent company of PharmEasy and Thyrocare, announced on Monday that it has repaid its entire outstanding debt of ₹1,050 crore, becoming debt-free after using proceeds from a partial sale of its Thyrocare stake and internal accruals. According to reports from The Hindu BusinessLine, the company achieved this milestone without ceding control of the diagnostics chain, retaining a 51.02 percent holding through its promoter entity Docon Technologies. For a company that spent much of the past few years battling questions around losses, leverage, and its path to profitability, the development marks a significant milestone. Alok Kumar Jagnani, Whole-Time Director and Group Chief Financial Officer, emphasized that the company "did it the hard way, without diluting our stake in Thyrocare below 51 per cent. That's the real headline: a stronger balance sheet without giving up our ownership."
The debt repayment follows Docon's sale of 1,57,69,696 Thyrocare shares, representing about 9.90 percent of the company's paid-up equity capital. As reported by The Hindu BusinessLine, the transaction generated funds that helped extinguish the group's term loan, while also triggering the release of pledges on the remaining Thyrocare shares. Docon's residual 51.02 percent stake is now entirely unencumbered, with the company managing to strengthen its balance sheet without allowing its Thyrocare ownership to fall below the critical 51% threshold. The latest sale raised approximately ₹986 crore through block deals at ₹624 per share, with buyers including Citigroup, Morgan Stanley, and HSBC Mutual Fund. The debt payment has also resulted in the release of the pledge on the remaining Thyrocare shares held by Docon, with the entire outstanding pledge linked to the debt now fully released.
According to Vice Chairman Siddharth Shah, shareholders who chose not to tender their shares during API Holdings' open offer at a bonus-adjusted price of ₹433 in July 2021 have seen returns of about 51 percent, including dividends, compared with roughly 41 percent delivered by the Nifty 50 over the same period. As reported by The Hindu BusinessLine, Thyrocare has emerged as one of the brighter spots within API Holdings' portfolio since the acquisition in 2021, with management arguing that those gains reflect a successful turnaround few expected when the acquisition was announced. The company recently reported strong Q1 FY27 results with revenue rising 24% year-on-year to ₹240 crore, profit after tax jumping 34% to ₹51 crore, and EBITDA growing 34% to ₹77 crore. It processed 55.2 million tests, up 28% during the quarter. Alok Kumar Jagnani noted that shareholders are now sitting on ₹653 at close of trading on 14th August 2026, representing a substantial appreciation from the original open offer price, with Siddharth Shah highlighting that "The Thyrocare acquisition has worked out well for API."
CEO Rahul Guha has outlined a strategic reverse merger plan where PharmEasy could potentially merge into the listed Thyrocare entity, provided the group meets two critical conditions. The first requirement is achieving debt-free status within days of the latest stake sale proceeds landing, which would eliminate the ₹1,050 crore of outstanding NCDs. The second condition involves API Holdings achieving pre-tax profitability excluding Thyrocare by the end of FY27, with PharmEasy expected to turn profitable within the next 3-4 quarters. Only after both these conditions are met will the company consider options including independent listing, reverse merger, or other strategic alternatives. Rahul Guha emphasized that "Zero debt isn't the finish line; it's the starting gun. This wasn't financial engineering; it was Thyrocare's and the group's execution, quarter after quarter, that made it possible."
The strategic positioning sets up a potential transformation where Thyrocare shareholders could gain exposure to PharmEasy through a reverse merger, creating a combined healthcare platform. However, this would involve swapping a profitable diagnostics business for a loss-making e-pharmacy in a competitive market. The latest stake sale has expanded Thyrocare's free float, with mutual funds already owning close to 20% of the company, making it more liquid and attractive to institutional investors. Despite the ongoing stake sales, Thyrocare's stock has rallied approximately 37% this year while the Sensex fell 8.5%, indicating strong investor confidence in the diagnostics business. With its term loan fully repaid and businesses moving into profitability, API Holdings enters its next phase focused on profitable growth and disciplined execution across its healthcare businesses, which include companies like PharmEasy, Ascent and Aknamed.
